CDKN2B
CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.
Overview
Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.
CIViC holds 8 clinical evidence items and 0 assertions across 5 variants, naming Palbociclib, Trametinib, Bevacizumab and Vemurafenib and others. Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.76, literature 0.98, genetic association 0.70, somatic mutation 0.62).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.
- 1 · What it is
CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Interacts strongly with CDK4 and CDK6. Potent inhibitor.
- 3 · How drugs use it
No product in this corpus aims at CDKN2B yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:1788 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42772 (protein name, function text, keywords and locations (REST API)); CIViC gene CDKN2B (8 evidence items, 0 assertions, 5 variants; diseases: Pancreatic Cancer, Cholangiocarcinoma, Ewing Sarcoma, Renal Cell Carcinoma, Acute Promyelocytic Leukaemia and 2 more (GraphQL API, CC0)); Open Targets ENSG00000147883 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: skin cancer 0.51, basal cell carcinoma 0.50, breast cancer 0.60 (GraphQL API, CC0))
Biology
Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. Location: Cytoplasm (UniProt). Locus 9p21.3 (HGNC).
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
- Renal cell carcinoma: CIViC evidence names this disease
- Breast cancer: Open Targets association 0.60 with breast cancer (MONDO_0007254)
- Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898)
- Biliary tract cancer: CIViC evidence names this disease
- Ewing sarcoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 9 therapies; CIViC holds 8 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Ganglioglioma.
Latest papers
topQuery for this target: (TITLE:"CDKN2B" OR ABSTRACT:"CDKN2B" OR TITLE:"cyclin dependent kinase inhibitor 2B" OR ABSTRACT:"cyclin dependent kinase inhibitor 2B" OR TITLE:"Cyclin-dependent kinase 4 inhibitor B" OR ABSTRACT:"Cyclin-dependent kinase 4 inhibitor B" OR TITLE:"P15" OR ABSTRACT:"P15" OR TITLE:"MTS2" OR ABSTRACT:"MTS2" OR TITLE:"INK4B" OR ABSTRACT:"INK4B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN2B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPTPRD
Shares Ewing sarcoma, Breast cancer (all types), CIViC, Pancreatic ductal adenocarcinoma.
- TargetPML
Shares Acute promyelocytic leukaemia, Skin cancer (all types), CIViC, Open Targets Platform.
- TargetCLTC
Shares Biliary tract cancer (cholangiocarcinoma), Renal cell carcinoma, Breast cancer (all types), Open Targets Platform.
- TargetRB1
Shares Small cell lung cancer (KEGG map), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetRARB
Shares Acute promyelocytic leukaemia, Open Targets Platform.
- TargetRARG
Shares Acute promyelocytic leukaemia, Open Targets Platform.
- TargetSLFN11
Shares Ewing sarcoma, CIViC.
- TrialPhase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Shares Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma.